PT - JOURNAL ARTICLE AU - Movahed, Mohammad Reza AU - Irannejad, Kyvan AU - Sadin, Fardokht AU - Keating, Luke AU - Bates, Sharon S. TI - Short-term effect of repeat echocardiographic screening for detection or confirmation of hypertrophic cardiomyopathy AID - 10.1101/2024.10.03.24314866 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.03.24314866 4099 - http://medrxiv.org/content/early/2024/10/04/2024.10.03.24314866.short 4100 - http://medrxiv.org/content/early/2024/10/04/2024.10.03.24314866.full AB - Background Diagnosis of Hypertrophic Cardiomyopathy (HCM) can be challenging. HCM can present later in life and the value of repeat echocardiogram for late presentation of HCM is not known. The goal of this study was to evaluate any changes in wall thickness occurring within 2 years using repeat screening echocardiography.Method The Anthony Bates Foundation has been performing screening echocardiography in high schools across the United States for the prevention of sudden death since 2001. A total of 206 subjects underwent baseline and repeat echocardiography within 2 years. We evaluated the prevalence of HCM before and after repeated echocardiography. Suspected HCM was defined as any wall thickness > 15 mm.Results The total prevalence of suspected HCM, defined by a cut-off value of 15 mm or more, was two from 206 (0.9%). Repeat echo within one year found one additional case of suspected HCM (wall thickness changed from 14 to 15 mm). However, the other two initial cases of suspected HCM showed regression of wall thickness to <15 mm not qualifying as HCM anymore as previously suspected after 2 years (one decreased wall thickness from 15 to 12 and the other one from 15 to 13 mm)Conclusion We found that repeat echocardiography is warranted in subjects with suspected HCM in order to prevent overdiagnosis. Furthermore, a new diagnosis of suspected cardiomyopathy was detected within 2 years of repeat screening. Larger studies are needed to evaluate the best timing and frequency of screening echocardiography for the detection and prevention of HCM.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo FundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and exempt by University of Arizona institutional review boardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNot available